Literature DB >> 23433410

Percutaneous computed tomography-guided renal mass radiofrequency ablation versus cryoablation: doses of sedation medication used.

Carl M Truesdale1, Michael C Soulen, Timothy W I Clark, Jeffrey I Mondschein, Eric Wehrenberg-Klee, S Bruce Malkowicz, Alan J Wein, Thomas J Guzzo, S William Stavropoulos.   

Abstract

PURPOSE: To compare the amount of sedation medication administered during radiofrequency (RF) ablation versus cryoablation of small renal masses.
MATERIALS AND METHODS: Records were retrospectively reviewed in patients who underwent percutaneous computed tomography-guided RF ablation and cryoablation of small renal masses from January 2002 to June 2011 for patient and tumor characteristics, amount of medications used for moderate sedation, and complications. Sedation was performed by giving patients titrated doses of midazolam and fentanyl. Additional medications were given if the desired level of sedation was not achieved.
RESULTS: There were 116 patients who underwent 136 ablation procedures; 71 patients underwent RF ablation, and 65 patients underwent cryoablation. RF ablation was associated with a significantly higher mean dose of fentanyl (mean dose for RF ablation, 236.43 μg; mean dose for cryoablation, 172.27 μg; P<.001). RF ablation was also associated with a higher mean dose of midazolam (mean dose for RF ablation, 4.5 mg; mean dose for cryoablation, 3.27 mg; P<.001). In the RF ablation group, two patients required additional sedation with droperidol. As a result of oversedation, two patients in the RF ablation cohort required sedation reversal with naloxone and flumazenil. None of the patients who underwent cryoablation required sedation reversal. No other sedation-related complications occurred.
CONCLUSIONS: Cryoablation of small renal masses was performed with less sedation medication than RF ablation. This finding suggests renal cryoablation is less painful than RF ablation; however, prospective studies with validated pain scales are needed to confirm these results.
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23433410     DOI: 10.1016/j.jvir.2012.11.022

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

Review 1.  Renal ablation update.

Authors:  Vishal Khiatani; Robert G Dixon
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

2.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

3.  Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study.

Authors:  Jack W Jennings; J David Prologo; Julien Garnon; Afshin Gangi; Xavier Buy; Jean Palussière; A Nicholas Kurup; Matthew Callstrom; Scott Genshaft; Fereidoun Abtin; Ambrose J Huang; Jason Iannuccilli; Frank Pilleul; Charles Mastier; Peter J Littrup; Thierry de Baère; Frédéric Deschamps
Journal:  Radiol Imaging Cancer       Date:  2021-02-12

4.  Image-guided cryoablation for the treatment of painful musculoskeletal metastatic disease: a single-center experience.

Authors:  J David Prologo; Matthew Passalacqua; Indravadan Patel; Nathan Bohnert; David J Corn
Journal:  Skeletal Radiol       Date:  2014-06-28       Impact factor: 2.199

5.  Comparative Outcome of Computed Tomography-guided Percutaneous Radiofrequency Ablation, Partial Nephrectomy or Radical Nephrectomy in the Treatment of Stage T1 Renal Cell Carcinoma.

Authors:  Chad J Cooper; Mohamed Teleb; Alok Dwivedi; Gabriela Rangel; Luis A Sanchez; Shaked Laks; Nassim Akle; Zeina Nahleh
Journal:  Rare Tumors       Date:  2015-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.